Drug Discovery Update:
WCK 5222 (ZAYNICH): We continue to recruit more patients for our global clinical trial and
have recruited 392 patients. Recruitment of more than 100 patients has been done during the
current quarter. Clinical Trial study progressing in 9 countries. We have completed 30 patients
for compassionate use after approval of usage by DCGI. The product resulted in 100% cure
and was found to be safe even when administered upto 60 days.
Meropenem Resistance Clinical Trial: DCGI has advised to do a Clinical Trial of 60 patients
study. Patient recruitment process has been initiated. This Clinical Trial would be completed
within the next 8 to 9 months post which WCK 5222 (ZAYNICH) can be launched in India by
early 2025.
WCK 4873 (MIQNAF): The Company is pleased to announce the completion of the pivotal
Phase 3 pneumonia study of its antibiotic Nafithromycin WCK 4873 (MIQNAF). The product
has been filed for DCGI approval which is expected in the Q3FY25. Commercial launch
expected in Q4FY25.
After 30 years, a new oral antibiotic MIQNAF (WCK 4873) will be shortly introduced in India
and it is for Community Acquired Pneumonia with a success rate of over 97%. This will meet
a major antibiotic community need as existing drugs like Azithromycin has high resistance of
60%. It is only a three-day treatment and it has eight times higher lung concentration than
Azithromycin
https://www.bseindia.com/xml-data/corpfiling/AttachLive/f975f9fc-b6fd-4fd7-972e-c8a1ca66ad3e.pdf
Subscribe To Our Free Newsletter |